ChiCTR2300073858 版本V1.1 版本创建时间2023/09/16 10:26:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300073858 

最近更新日期:

Date of Last Refreshed on:

2023-07-24 11:06:58 

注册时间:

Date of Registration:

2023-07-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于COM-B+BCTs的慢性心力衰竭患者体质量管理方案的构建及初步应用

Public title:

Construction and preliminary application of a physical quality management program for patients with chronic heart failure based on COM-B+BCTs

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于COM-B+BCTs的慢性心力衰竭患者体质量管理方案的构建及初步应用

Scientific title:

Construction and preliminary application of a physical quality management program for patients with chronic heart failure based on COM-B+BCTs

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

薛亚男 

研究负责人:

薛亚男 

Applicant:

Xue Yanan 

Study leader:

Xue Yanan 

申请注册联系人电话:

Applicant telephone:

+86 180 9887 3306

研究负责人电话:

Study leader's
telephone:

+86 180 9887 3306

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

248863229@qq.com

研究负责人电子邮件:

Study leader's E-mail:

248863229@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省大连市沙河口区联合路193号

研究负责人通讯地址:

辽宁省大连市沙河口区联合路193号

Applicant address:

Liaoning Province, Dalian City, Shahekou District, Union Road No. 193.

Study leader's address:

Liaoning Province, Dalian City, Shahekou District, Union Road No. 193.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大连医科大学附属第一医院

Applicant's institution:

Dalian Medical University Affiliated First Hospital

研究负责人所在单位:

大连医科大学附属第一医院

Affiliation of the Leader:

Dalian Medical University Affiliated First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

PJ-KS-KY-2023-226(X)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

大连医科大学附属第一医院伦理委员会

Name of the ethic committee:

Dalian Medical University Affiliated First Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-13 00:00:00

伦理委员会联系人:

徐蕾

Contact Name of the ethic committee:

Xu Lei

伦理委员会联系地址:

大连市西岗区中山路222号大连医科大学附属第一医院一部四楼行政办公区4008伦理办公室

Contact Address of the ethic committee:

The administrative office of the Ethics Department, Room 4008, is located on the fourth floor of the Affiliated First Hospital of Dalian Medical University, No. 222 Zhongshan Road, Xigang District, Dalian City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 411 8363 5963

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

大连医科大学附属第一医院

Primary sponsor:

Dalian Medical University Affiliated First Hospital

研究实施负责(组长)单位地址:

大连医科大学附属第一医院

Primary sponsor's address:

Dalian Medical University Affiliated First Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

大连

市(区县):

Country:

China

Province:

Dalian

City:

单位(医院):

大连医科大学附属第一医院

具体地址:

大连市西岗区中山路222号大连医科大学附属第一医院

Institution
hospital:

Dalian Medical University Affiliated First Hospital

Address:

Dalian Medical University Affiliated First Hospital, located at No. 222 Zhongshan Road, Xigang District, Dalian City

经费或物资来源:

Source(s) of funding:

None

研究疾病:

慢性心力衰竭  

Target disease:

Chronic heart failure

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

(1)基于COM-B+BCTs构建慢性心力衰竭患者体质量管理方案,并通过专家咨询形成干预方案; (2)探讨干预方案对慢性心力衰竭患者体质量管理行为能力、心功能与生活质量的影响,提高CHF患者体质量管理行为能力,为临床实践提供科学依据。  

Objectives of Study:

(1) Build a comprehensive management program for patients with chronic heart failure based on COM-B+BCTs, and formulate intervention plans through expert consultation; (2) Explore the impact of the intervention plans on the behavioral capacity, cardiac function, and quality of life of patients with chronic heart failure, improve the behavioral capacity for managing physical quality in CHF patients, and provide scientific evidence for clinical practice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合2018年《中国心力衰竭诊断和治疗指南》诊断标准,且病程在3个月以上; (2)无精神疾患和认知障碍,可正常交流; (3)年龄≥18岁,自愿参与本此调查。

Inclusion criteria

(1) Meet the diagnostic criteria of the 2018 Chinese Heart Failure Diagnosis and Treatment Guidelines, with a disease course of more than 3 months; (2) No mental illness or cognitive impairment, able to communicate normally; (3) Age ≥ 18 years old, voluntarily participate in this survey.

排除标准:

(1)生活不能自理者; (2)难治性终末期心力衰竭; (3)合并严重的其他系统疾病。

Exclusion criteria:

(1) Individuals who are unable to care for themselves in daily life; (2) Patients with incurable terminal heart failure; (3) Those who have severe comorbidities with other systemic diseases.

研究实施时间:

Study execute time:

From 2023-07-24 00:00:00 To 2024-02-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-24 00:00:00 To 2023-08-31 00:00:00

干预措施:

Interventions:

组别:

研究组(实施体质量管理干预)

样本量:

30

Group:

Research group (implementing quality management intervention)

Sample size:

干预措施:

实施体质量管理干预方案

干预措施代码:

Intervention:

Implementing a quality management intervention program.

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

无干预

干预措施代码:

Intervention:

without intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

大连 

市(区县):

 

Country:

China

Province:

Dalian

City:

单位(医院):

大连医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

Dalian Medical University Affiliated First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

体质量管理行为

指标类型:

主要指标

Outcome:

Quality management behavior

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NYHA心功能分级

指标类型:

次要指标

Outcome:

NYHA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氨基末端脑利钠肽前体

指标类型:

次要指标

Outcome:

NT-proBNP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脏彩超左心室射血分数

指标类型:

次要指标

Outcome:

LVEF

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开原始数据的日期为2024年7月,以原始数据录入表格形式呈现

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The date for the release of the original data is July 2024, presented in the form of a table containing the original data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

问卷及相关检查结果回收后,双人核对录入病例记录表,采用 SPSS26.0进行数据的录入、处理与分析,运用描述性统计(计量资料使用均数、标准差、中位数、四分位数等进行统计描述;计数资料采用频数、百分比等进行统计描述)、T 检验、单因素方差分析及多元线性回归等方法进行统计学分析,P< 0.05为差异有统计学意义。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

After the questionnaire and related examination results were collected, the case records were double-checked and entered into the SPSS 26.0 software for data entry, processing, and analysis. Descriptive statistics (mean, standard deviation, median, quartiles, etc.) were used for quantitative data, while frequency and percentage were used for categorical data. Statistical analysis was conducted using methods such as t-test, one-way analysis of variance, and multiple linear regression. A p-value less than 0.05 was considered statistically significant.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-07-24 11:04:58